| Literature DB >> 31396204 |
Madhu Chhanda Mohanty1, Manisha Ranjan Madkaikar2, Mukesh Desai3, Jahnavi Aluri2, Swapnil Yashwant Varose1, Prasad Taur3, Deepa Kailash Sharma1, Uma Prajwal Nalavade1, Sneha Vijay Rane1, Maya Gupta2, Snehal Shabarish2, Aparna Dalvi2, Jagadish Mohanrao Deshpande1.
Abstract
The emergence of immunodeficiency-associated vaccine-derived polioviruses (iVDPV) from children with primary immunodeficiency disorders poses a threat to the eradication program. Herein, we report a patient with severe combined immunodeficiency (SCID), identified as a prolonged serotype 3 iVDPV (iVDPV3) excreter with 13 VDPV3 isolates and a maximum of 10.33% nucleotide divergence, who abruptly cleared infection after a period of 2 years. Occurrence of an episode of norovirus diarrhea associated with increased activated oligoclonal cytotoxic T cells, inverse CD4:CD8 ratio, significantly elevated pro-inflammatory cytokines, and subsequent clearance of the poliovirus suggests a possible link between inflammatory diarrheal illness and clearance of iVDPV. Our findings suggest that in the absence of B cells and sufficiently activated T/NK cells, macrophages and other T cells may produce auto-inflammatory conditions by TLR/RLR ligands expressed by previous/ongoing bacterial or viral infections to clear VDPV infection. The study highlights the need to screen all the patients with combined immunodeficiency for poliovirus excretion and intermittent follow-up of their immune parameters if found positive, in order to manage the risk of iVDPV excretion in the polio eradication endgame strategy.Entities:
Keywords: inflammatory cytokines; leaky SCID; oral polio vaccine; primary immunodeficiency disorder; severe combined immune-deficiency; vaccine-derived polioviruses
Mesh:
Substances:
Year: 2019 PMID: 31396204 PMCID: PMC6663979 DOI: 10.3389/fimmu.2019.01567
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Characteristics of the SCID patient excreting vaccine-derived poliovirus.
| Age at hospitalization, months | 48 |
| Sex | Male |
| Immunodeficiency type | Severe combined immunodeficiency (SCID) |
| Diagnosis of immunodeficiency (months) | 16 |
| OPV doses | Routine (birth, 6, 10, and 14 weeks) pulse polio up to 14 months of age |
| IPV | 42 |
| Other vaccinations | DPT |
| Period of poliovirus excretion after 1st detection, months | 24 |
| Estimated total time of virus excretion at the time of detection, months | ~48 |
| Estimated total time of poliovirus excretion, months | 73 |
| Maximum nucleotide differences | 93 |
| Neutralizing antibody tires | |
| Against poliovirus type 1 | 6 |
| Against poliovirus type 2 | 7 |
| Against poliovirus type 3 | 28 |
Inactivated polio vaccine.
Diphtheria, pertussis tetanus (vaccine).
With parent Sabin strain.
Reciprocate titers 1:6, 1:7, 1:28.
Clinical presentations of the SCID patient during hospital admissions.
| 11 | Bacillary dysentery |
| 14 | Tuberculosis |
| 24 | Pneumonia |
| 30 | Loose motion ( |
| 48 | UTI |
| 54 | UTI |
| 60 | Pneumonia, UTI ( |
| 70 | Hypocalcaemia |
| 73 | Persistent loose motion, diarrhea (Norovirus), CMV |
| 80 | Acute gastroenteritis with anemia |
| 92 | Loose motion, high-grade fever |
Urinary tract infection.
Cytomegalovirus positive.
History of virus isolation from the SCID patient.
| 1 | 50 | 04-09-2014 | P3DIS | P3VDPV | 41 | 4.56 |
| 2 | 53 | 04-12-2014 | P3DIS | P3VDPV | 46 | 5.11 |
| 3 | 55 | 26-02-2015 | P3DIS | P3VDPV | 49 | 5.44 |
| 4 | 56 | 30-03-2015 | P3DIS | P3VDPV | 48 | 5.33 |
| 5 | 58 | 25-05-2015 | P3DIS | P3VDPV | 55 | 6.11 |
| 6 | 61 | 04-08-2015 | P3DIS | P3VDPV | 61 | 6.78 |
| 7 | 63 | 05-10-2015 | P3DIS | P3VDPV | 64 | 7.11 |
| 8 | 65 | 02-12-2015 | P3DIS | P3VDPV | 73 | 8.11 |
| 9 | 66 | 05-01-2016 | P3DIS | P3VDPV | 66 | 7.33 |
| 10 | 67 | 10-02-2016 | P3DIS | P3VDPV | 93 | 10.33 |
| 11 | 68 | 07-03-2016 | P3DIS | P3VDPV | 68 | 7.56 |
| 12 | 70 | 30-05-2016 | P3DIS | P3VDPV | 67 | 7.44 |
| 13 | 73 | 04-08-2016 | P3DIS | P3VDPV | 76 | 8.44 |
| 14 | 75 | 31-10-2016 | Negative | Negative | Nil | Nil |
| 15 | 76 | 21-11-2016 | Negative | Negative | Nil | Nil |
Intratypic differentiation.
Poliovirus type 3 discordant.
To date.
Figure 1The accumulation of changes in the VP1 genomic region of 13 sequential poliovirus type 3 isolates under study. The actual observed data and the variability of the repeated measurements over the time of observation have been indicated. The data were adjusted to linear functions for the accumulation of substitutions. The two lines show the best-fitting linear trend to the observed positive data with and without an intercept. The line with no intercept implies infection at the time of birth, because it goes through 0% divergence at age 0. The better-fitting line with the intercept shows a steeper increase in divergence. Regression with intercept: equation for the line: estimated % divergence while excreting Y = 0.112 x, x = age (months), Y = estimated % divergence, R2 = 0.85. Regression without intercept: equation for the line: estimated % divergence while excreting Y = 0.192x – 5, where x = age (months), Y = estimated % divergence, R2 = 0.99.
Immune profile of the SCID patient from the time of diagnosis up to the age of 7 years.
| ALC/mm3 | 3,753 | 6,647 | 3,600–890 | 3,400 | 3,355 | 2,300–5,400 | 9,255 | 6,360 | 1,900–3,700 |
| CD19+/B lymphocytes | 150 | 598 | 720–2,600 | 884 | 101 | 390–1,400 | 185 | 191 | 270–860 |
| CD3+T lymphocytes | 1,989 | 2,061 | 2,100–6,200 | 1,054 | 1,845 | 1,400–3,700 | 6,664 | 4,833 | 1,200–2,600 |
| CD3+/CD4+ Th lymphocytes | 826 | 465 | 1,300–3,400 | 816 | 336 | 700–2,200 | 1,111 | 700 | 650–1,500 |
| CD3+/CD8+ Tc lymphocytes | 826 | 997 | 620–2,000 | 204 | 1,007 | 490–1,300 | 3,610 | 2,798 | 370–1,100 |
| CD3–/CD16+56+ NK Cells | 1,576 | 3,789 | 180–920 | 1,360 | 1,275 | 130–720 | 2,314 | 1,272 | 100–480 |
Surface markers for flow cytometry contained FITC-labeled CD3, PE-labeled CD16, and CD56, PerCP. Cy.
Lymphocyte count of the last sample collected when the child was shedding VDPV3.
Lymphocyte count of the first sample collected after the child stopped VDPV3 shedding.
Quantification of serum Ig concentration of the SCID patient at different time points.
| IgG, g/L | <1.41 | 2.23 | 9.95 | 0.12 | 0.5 | 0.99 | 3.5–16.2 |
| IgA, g/L | <0.244 | NA | 0.47 | 0.002 | 0.004 | 0.004 | 0.17–3.18 |
| IgM, g/L | 0.203 | 0.206 | – | – | <0.168 | <0.168 | 0.30–2.65 |
| IgE, IU/ml | <15.3 | <15.3 | – | – | <4.45 | <17.8 | 3–423 |
Serum Ig quantified by nephelometry (below cutoff range). Values without star mark were quantified by IgG/A ELISA (absolute values).
Sample collected after IVIG administration.
International Units/milliliter.
Figure 2Estimation of cytokine/chemokine levels in the serum samples of the SCID patient tested positive for VDPV3 and abruptly stopped poliovirus shedding after 2 years of continuous excretion at the age of 6 years. The serum samples collected from the child during poliovirus excretion period (4 and 5th year) and after viral clearance (6 and 7th year) were tested by multiplex cytokine ELISA. The assays were performed twice and the mean and standard error were considered for evaluating the statistical significance by Student's t-test. * represents p < 0.05, ** represent p < 0.01, and *** indicate p < 0.001. (A) Estimation of pro-inflammatory cytokine levels. (B) Estimation of Th2 cytokine levels. (C) Estimation of interferon levels. (D) Estimation of chemokine levels in the SCID patient before and after poliovirus clearance.